Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

Cassava Faces Renewed Speculation Over Experimental Alzheimer’s Drug
Cassava Faces Renewed Speculation Over Experimental Alzheimer’s Drug
Shares of Cassava Sciences plunged Tuesday in premarket trading after multiple Alzheimer’s researchers raised new concerns about the company’s experimental Alzheimer’s treatment, simufilam. ...
NICE Recommends Merck Serono’s NSCLC Drug Tepmetko
NICE Recommends Merck Serono’s NSCLC Drug Tepmetko
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Merck Serono’s Tepmetko (tepotinib) for National Health Service (NHS) use in the treatment of certain adult pa...
House Committee Targets McKinsey for Dealings With Drugmakers and the FDA
House Committee Targets McKinsey for Dealings With Drugmakers and the FDA
The House Committee on Oversight and Reform has put out a staff report that calls out consulting firm McKinsey for simultaneously providing its services to pharmaceutical companies — including P...
Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine
Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine
Merck, known as MSD outside the United States and Canada, announced today that V116, the company’s investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Des...
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
BriaCell Therapeutics Corp. , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the U.S. Food and Drug Administration (FDA) has granted Fast...
Vitamin E can boost immunotherapy responses by reinvigorating dendritic cells
Vitamin E can boost immunotherapy responses by reinvigorating dendritic cells
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson Cancer Center have discovered that vitamin E can enhance...
U.S. FDA delays decision on Regeneron/Roche COVID antibody therapy
U.S. FDA delays decision on Regeneron/Roche COVID antibody therapy
The U.S. Food and Drug Administration has extended by three months its review of Regeneron Pharmaceuticals Inc's application for the full approval of its COVID-19 antibody therapy, the U.S. drugma...
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin
Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referenci...
NICE Recommends Biogen’s Multiple Sclerosis Drug Vumerity
NICE Recommends Biogen’s Multiple Sclerosis Drug Vumerity
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Biogen’s Vumerity (diroximel fumarate) for National Health Service (NHS) use for the treatment of relapsing-rem...
Shionogi’s Investigational COVID-19 Drug Linked to Fetal Abnormalities
Shionogi’s Investigational COVID-19 Drug Linked to Fetal Abnormalities
Shionogi has confirmed reports that its investigational COVID-19 drug, S-217622, led to fetal abnormalities in a preclinical study. ...
Halozyme Therapeutics to Acquire Antares Pharma for Nearly $1 Billion
Halozyme Therapeutics to Acquire Antares Pharma for Nearly $1 Billion

San Diego, Calif.-based Halozyme Therapeutics is purchasing Ewing, N.J.-headquartered Antares Pharma in a deal valued at approximately $960 million.

Bristol Myers Squibb Publishes Promising Phase 3 Data on New Opdivo Indication
Bristol Myers Squibb Publishes Promising Phase 3 Data on New Opdivo Indication
Bristol Myers Squibb’s blockbuster drug Opdivo (nivolumab) has met its primary endpoint of event-free survival in a phase 3 trial compared to chemotherapy alone in patients with resectable nonsma...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand